Novo Nordisk announced its CagriSema GLP-1 weight loss drug underperformed Eli Lilly's tirzepatide in a trial. Separately, Lilly announced patients can use a single injector to hold a month's supply ...
It’s a good day to be the pharmaceutical giant Eli Lilly. Right now, Eli Lilly appears to be the leader in the GLP-1 race amid multiple difficult headwinds for Novo Nordisk. As of this writing, Novo ...
Eli Lilly (LLY) reported Q4 EPS of $7.54 versus $6.67 expected. Eli Lilly projected 2026 revenue of $80-83B. Eli Lilly’s Mounjaro revenue surged 110% to $7.4B in Q4. Zepbound revenue jumped 123% to $4 ...
Determined to avoid a repeat of the supply shortfalls that plagued early GLP-1 rollouts for obesity, Eli Lilly has amassed a sizable store of its oral weight loss candidate orforglipron. Specifically, ...
Aaron McDade is a breaking news reporter for Investopedia. He is an experienced journalist who has covered everything from the latest in business and tech news to sports and international news like ...
Eli Lilly is rated SELL due to lofty valuation, despite extraordinary execution and recent market leadership in GLP-1 and obesity drugs. LLY's current $950B market cap implies sustained 25% annual ...
Profit and revenue forecasts for 2026 well above Street view Lilly's Q4 profit and revenue exceed expectations Lilly's obesity drug Zepbound boosts sales despite price cuts Lilly's orforglipron pill ...
Global pharmaceutical firm Eli Lilly and Co. will invest $3.5 billion to build a manufacturing plant in Upper Macungie Township that is expected to create 850 jobs. “This is the largest single project ...
Mock up of Eli Lilly's manufacturing site in the Lehigh Valley (Eli Lilly/Cision) Eli Lilly is expanding its footprint in eastern Pennsylvania with a new manufacturing site outside of Philadelphia.
For Evangeline Lilly, the road to recovery doesn't have to be lonely. The Golden Globe-nominated actress, who has been navigating a traumatic brain injury, opened up about her recovery efforts in an ...
GLP-1 giant Eli Lilly has once again taken to the medium of short film to deliver an important message about obesity. In early 2024, the Big Pharma debuted a pair of unbranded shorts entitled “Big ...
How Evangeline Lilly is doing now. When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. In May 2025, Evangeline Lilly posted on her Substack that she ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results